MedPath

HEAL Initiative's JCOIN Phase II Focuses on Opioid Use Disorder Treatment in Justice-Involved Populations

• The HEAL Initiative's JCOIN Phase II targets individuals in the US justice system who are disproportionately affected by substance use disorders (SUD) and opioid use disorder (OUD). • The initiative aims to increase the delivery of and access to medication-assisted treatment (MOUD) within criminal justice settings to combat the overdose crisis. • JCOIN supports research projects that conduct hybrid effectiveness-implementation trials to address barriers to evidence-based OUD treatments for justice-involved populations. • This initiative is the only HEAL program with a primary focus on addressing the opioid crisis within criminal-legal systems, emphasizing research-to-practice translation.

The Health Resources and Services Administration (HRSA) is spearheading the HEAL Initiative's JCOIN Phase II Community Engaged Research Resource Center, with a focus on addressing the opioid crisis among individuals involved in the US justice system. This initiative recognizes that individuals within the justice system are at a disproportionately high risk for SUD/OUD, opioid withdrawal upon incarceration, and overdose post-release, particularly if they have not received medication-assisted treatment (MOUD) while detained.

Addressing a Critical Need

Most US jails currently do not offer MOUD to all individuals who could benefit from it, creating a significant gap in care. JCOIN Phase II aims to bridge this gap by focusing on the translation of research into practical applications within the criminal justice system. The core objective is to increase both the delivery of and access to MOUD, thereby mitigating the overdose crisis within this vulnerable population.

Research and Implementation

A portfolio of research projects will conduct hybrid effectiveness-implementation trials. These trials are designed to identify and address key barriers that impede the delivery of evidence-based OUD treatments to justice-involved individuals. By focusing on practical implementation, JCOIN seeks to ensure that research findings are effectively translated into tangible improvements in treatment access and outcomes.

Unique Focus within HEAL

JCOIN stands out as the only initiative within the broader HEAL program that is primarily focused on justice-involved populations and the criminal-legal system. This targeted approach allows for a more specialized and effective response to the unique challenges faced by this demographic in accessing and benefiting from OUD treatments. The application deadline is January 22, 2025.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

STEP-2 Trial of Cervical Cancer Screening Interventions Joins the NIH Collaboratory

The NIH Pragmatic Trials Collaboratory welcomes the STEP-2 trial, focusing on cervical cancer screening through self-sampling kits in underserved populations, to its portfolio. This trial aims to address the low screening rates exacerbated by the COVID-19 pandemic by evaluating the effectiveness of different distribution methods of HPV self-sampling kits.

Kidney Cancer Research Consortium Advances Novel Immunotherapy and Targeted Therapies

The Kidney Cancer Research Consortium is dedicated to improving renal cell carcinoma treatment through innovative clinical trials and novel agents.
Trials are evaluating combinations of immune checkpoint inhibitors with agents like ciforadenant and evolocumab to enhance immune response.

Open Philanthropy Awards $1.5 Million to Cures Within Reach for Repurposing Research in LMICs

Cures Within Reach (CWR) receives $1.5 million from Open Philanthropy to support clinical trials in low- and middle-income countries (LMICs).
The funding will support CWR's ReGRoW initiative, which focuses on repurposing readily available generic medicines and indigenous treatments.

Cures Within Reach Expands Clinical Trials in LMICs to Address High Disease Burden

Cures Within Reach (CWR) and Open Philanthropy are funding 16 new clinical trials in low and lower-middle income countries (LMICs) to explore affordable treatments using existing medicines.
A Phase 2B clinical trial in Brazil and Ghana will test unithiol and marimastat as inexpensive oral treatments for snakebites, following promising Phase 1 results in Kenya.

Sen-Jam's SJP-001 Hangover Prevention Therapy Enters Phase 2 Trial

Sen-Jam Pharmaceutical has initiated a Phase 2 clinical trial in Australia for SJP-001, a novel therapy aimed at preventing hangovers by targeting inflammation.
SJP-001 combines naproxen and fexofenadine to mitigate the inflammatory response triggered by alcohol consumption, potentially reducing hangover severity and duration.

Yale Team Awarded $76M NIH Grant to Study Schizophrenia Risk in Youth

Yale University scientists have received a $76 million NIH grant to study young people at high risk for psychosis as part of the AMP® SCZ program.
The five-year study will evaluate drug compounds for their potential to impact biological, digital, cognitive, or clinical outcomes in at-risk individuals.

NIH Launches CARE for Health Network to Enhance Primary Care Research

The NIH is investing $30 million to launch the CARE for Health network, aimed at integrating clinical research with community-based primary care.
Three inaugural research hubs have been selected at Oregon Health and Science University (OHSU), University of Wisconsin-Madison (UW), and West Virginia University (WVU).

Jackson Laboratory's MCGI Studies Impact of Genomic Tumor Boards and HER2 in Cancer Care

The Maine Cancer Genomics Initiative (MCGI) is expanding access to precision medicine for oncologists in rural and underserved areas.
MCGI, in collaboration with Columbia University, is studying the impact of Genomic Tumor Boards on cancer care delivery nationwide.

Servier and Clariness Collaborate on Phase II Trial for Sjögren's Syndrome Drug

Servier and Clariness are collaborating on a Phase II trial to develop a novel biological therapy for primary Sjögren's syndrome, an autoimmune disease affecting salivary and lacrimal glands.
The investigational drug uses an antibody to suppress inflammatory processes associated with Sjögren's syndrome, addressing the unmet need for targeted treatments.

First Patient Dosed in Guard Therapeutics' Phase 2b Study POINTER

Guard Therapeutics has announced the dosing of the first patient in its phase 2b clinical study, POINTER, evaluating RMC-035 as a kidney-protective treatment during open-heart surgery. The study, starting in Canada and expanding to Europe, aims to determine the optimal dosing regimen and target population for RMC-035.

Reference News

[1]
HEAL Initiative: JCOIN Phase II Community Engaged Research Resource Center - Josh Gottheimer
gottheimer.house.gov · Oct 22, 2024

HEAL Initiative: JCOIN Phase II focuses on increasing MOUD access for justice-involved populations, addressing overdose ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy